BD Invests 19 Billion to Strengthen US Medical Manufacturing

In October 2026, BD entered into an agreement with the U.S. Government to expand domestic manufacturing and strengthen the resilience of the American healthcare supply chain. The partnership is focused on increasing U.S. production of essential medical consumables, strengthening domestic manufacturing capabilities, and supporting reliable access to critical medical technologies.

Under the agreement, BD plans to invest $19 billion in the United States over several years across capital, operational, and supply chain activities. Of this amount, approximately $3 billion is expected to be directed toward expanding U.S. manufacturing at strategic production sites. The company also plans to increase domestic production by approximately 5 billion essential medical consumables annually.

The initiative is expected to increase BD’s share of domestically supplied essential medical consumables to approximately 80%. BD has also committed to manufacturing 100% of its needles used in America domestically using American-made steel. These commitments are designed to strengthen domestic production and reduce vulnerabilities associated with complex global healthcare supply chains.

The partnership is significant for the medical technology industry because  BD supplies products that are widely  used across healthcare settings. The company has stated that its products are involved in approximately 90% of U.S. hospital visits, highlighting the importance of maintaining reliable access to its medical consumables.

Focus on Expanding Domestic Medical Manufacturing

The central objective of the partnership is to increase manufacturing capacity within the United States. BD’s planned $3 billion manufacturing investment will support expansion across multiple production locations, creating additional capacity for essential medical consumables.

The company expects the investment to add approximately 5 billion products to annual U.S. production. These products are used in routine healthcare laboratories and other aspects of patient care.

The initiatives also reflect a broader shift in medical technology manufacturing. Companies are increasingly considering where products are manufactured, where raw materials are sourced, and how supply networks can respond to disruptions.

BD’s existing U.S. manufacturing footprint includes facilities in Nebraska, Connecticut, Puerto Rico, Utah, Texas, Georgia, and South Carolina. The new investment is expected to build on this established network and expand the company’s ability to manufacture essential healthcare products domestically.

Strengthening Healthcare Supply Chain Resilience

Healthcare supply chain resilience has become an important priority for government, healthcare providers, and medical technology companies. Disruption involving raw materials, transportation, international trade, manufacturing capacity, or unexpected increases in demand can affect the availability of essential healthcare products.

The BD-U.S. Government partnership is designed to strengthen the supply chain by increasing domestic manufacturing capacity. Producing a larger proportion of essential medical consumables within the United States could provide additional supply flexibility and reduce exposure to certain international supply chain disruptions.

The planned increase in domestic production is particularly relevant for products that are routinely used throughout the healthcare system. Hospitals require a continuous supply of medical consumables to maintain normal clinical operations.

The initiative therefore goes beyond increasing manufacturing output. It represents an effort to strengthen the infrastructure supporting healthcare delivery by creating additional production capacity closer to the end users.

A stronger domestic manufacturing base could also help the healthcare system respond more effectively to periods of increased demand. During public health emergencies or other unexpected events, domestic production capacity can become an important component of healthcare preparedness.

Impact on the Medical Technology Market

The partnership could have a significant impact on the U.S. medical technology market by encouraging greater investment in domestic production. BD’s $19 billion commitment represents a substantial long-term investment in the country’s medical manufacturing and supply chain infrastructure.

The $3 billion in manufacturing components is particularly important because it is directly focused on increasing production capacity. Such investment can support manufacturing facilities, production equipment, operational capabilities, quality systems, and related infrastructure.

The expansion may also influence other medical technology companies as they evaluate their own manufacturing strategies. If domestic production becomes increasingly important to healthcare security and government policy, manufacturers may consider expanding U.S. production or strengthening relationships with domestic suppliers.

Greater manufacturing investment can also create opportunities for technological modernization. Medical device companies may adopt automation, digital manufacturing systems, advanced quality-control technologies, and improved production monitoring to increase efficiency while maintaining strict quality standards.

The effects could therefore extend beyond BD itself. Increased demand for domestic manufacturing services, raw materials, engineering capabilities, logistics, and technical expertise could support a broader ecosystem around medical technology production.

For the medical device industry, the agreement demonstrate how manufacturing strategy is becoming increasingly connected with healthcare resilience and national supply security.

Focus on Domestic Needle Production

One of the most notable commitments under the agreement is BD’s plan to manufacture 100% of the needles it uses in America domestically using American-made steel.

Needle are among the most widely used medical consumables in healthcare. They support activities such as injection, blood collection, medication administration, and other clinical procedures.

Domestic manufacturing of needles using American-made steel would increase the level of localization across the production process. Rather than concentrating only on final assembly, the approach also emphasizes domestic sourcing of an important raw material.

This could strengthen the connection between U.S. raw material supplies and medical device manufacturers. A stronger domestic supply network could provide greater visibility and control over the availability of materials required for production.

The commitment also demonstrates the broader importance of upstream supply chains in healthcare manufacturing. Reliable access to finished medical products depends not only on manufacturing facilities but also on the availability of raw materials and components.

As medical technology companies seek to improve supply chain resilience, domestic sourcing of critical materials could become a more important part of manufacturing strategies.

Impact on Medical Device Supply Chains

The agreement could influence the structure of medical device supply chains by increasing the importance of domestic manufacturing and sourcing.

BD expects the initiative to increase its share of domestically supplied essential medical consumables to approximately 80%. This represents a major shift toward domestic supply for products used across the U.S. healthcare system.

For healthcare providers, stronger domestic production could support greater supply reliability. Hospitals and other facilities depend on predictable access to essential products, particularly those used in high volumes.

Domestic production may also reduce some logistical complexity associated with long-distance international supply chains. Shorter or more localized supply networks can potentially improve responsiveness to changes in demand.

However, supply chain resilience requires more than domestic manufacturing alone. Companies must also maintain reliable access to raw materials, qualified suppliers, skilled workers, transportation, quality systems, and manufacturing technologies.

BD strategy addresses several of these elements through its focus on manufacturing investment, domestic needle production, and supply chain expenditure.

Government and Industry Collaboration

The partnership demonstrates the growing importance of collaboration between government and the private healthcare industry in strengthening medical supply chains.

Government policies can influence manufacturing investment through trade regulations, tariffs, incentives, and strategic initiatives. Healthcare companies, meanwhile, contribute capital, manufacturing infrastructure, technology, workforce expertise, and knowledge of healthcare product requirements.

The BD agreement brings these interests together around the goal of strengthening U.S. healthcare manufacturing.  

Such collaboration can be particularly important for essential medical products because their availability has implications beyond individual companies. A reliable supply of needles, syringes, and other healthcare facilities.

The partnership could also encourage additional investments across the medical consumables sector to support the operation of hospitals, clinics, laboratories, and other healthcare facilities.

The partnership could also encourage additional investment across the medical device industry. Other manufacturers may evaluate whether expanding domestic production could improve supply security while supporting long-term business growth.

The approach highlights how healthcare manufacturing can become part of broader national preparedness strategies.

Opportunities for the U.S. Healthcare Industry

The partnership creates several potential opportunities for the U.S. healthcare industry. One of the most important is the development of additional domestic manufacturing capacity for essential medical products.

Increased production could support a more robust medical supply ecosystem while creating demand for manufacturing technology, engineering services, raw materials, logistics, and skilled workers.

Another opportunity is the modernization of medical manufacturing. As companies expand production facilities, they may incorporate advanced technologies designed to improve productivity, quality, traceability, and operational efficiency.

The initiative may also encourage further collaboration between medical technology manufacturers and domestic suppliers. Stronger supplier networks could provide additional resilience across the healthcare manufacturing ecosystem.

There may also be opportunities for research and development in manufacturing processes. Increased investment in production infrastructure can support the adoption of new technologies that improve the efficiency and reliability of medical device production.

For the broader healthcare industry, these developments could contribute to a stronger connection between manufacturing innovation and healthcare preparedness.

Future Opportunities

The BD partnership could create long-term opportunities for the U.S. medical technology and healthcare manufacturing sectors. One major opportunity is the continued expansion of domestic production for products considered essential to patient care.

As governments and healthcare systems place greater emphasis on supply chain security, domestic manufacturing could become an increasingly important factor in medical device investment decisions.

The development of advanced manufacturing facilities may also support greater automation and digitalization. Technologies such as automated production systems, digital quality monitoring, predictive maintenance, and supply chain analytics could help manufacturers increase output while maintaining quality requirements.

Another opportunity is the strengthening of domestic raw material supply chains. BD's commitment to using American-made steel for needles illustrates how localization can extend beyond finished medical products.

The agreement could also encourage other healthcare manufacturers to examine similar strategies. Increased investment in domestic manufacturing could gradually create a broader ecosystem capable of supporting the production of critical healthcare supplies.

Over the longer term, stronger domestic manufacturing could help position the United States as a more resilient center for medical technology production.

Conclusion

The partnership between BD and the U.S. Government marks a significant development in U.S. medical manufacturing and healthcare supply chain resilience.

Through its planned $19 billion investment, including $3 billion for manufacturing expansion, BD aims to increase domestic production of essential medical consumables and strengthen the country's healthcare manufacturing infrastructure.

The company expects to increase annual U.S. production by approximately 5 billion essential medical consumables and raise its share of domestically supplied products to around 80%. Its commitment to manufacture 100% of its needles used in America domestically using American-made steel further strengthens the focus on domestic sourcing and production.

The agreement also highlights the growing role of government-industry collaboration in addressing healthcare supply chain challenges. By combining government policy with private-sector investment and manufacturing capabilities, the initiative could support a more resilient medical technology ecosystem.

As healthcare systems continue to prioritize supply security, manufacturing capacity, and preparedness, domestic production is likely to remain an important area of focus. The BD partnership therefore represents a notable step toward strengthening U.S. medical manufacturing while supporting reliable access to essential healthcare products.